Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma.

Lambert, Nathalie; Guiddir, Tamazoust; Amat, Flore; Just, Jocelyne

Lambert, Nathalie; Guiddir, Tamazoust; Amat, Flore; Just, Jocelyne.

Affiliation

Lambert N; Allergology Department, Centre de l'Asthme et des Allergies, Hôpital d'Enfants Armand-Trousseau - 26, Paris Cedex 12, France; INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Sorbonne Universités, UPMC Univ Paris 06, Paris, France.

Pediatr Allergy Immunol ; 25(8): 829-32, 2014 Dec.

Article in En | MEDLINE | ID: mdl-25387446

Subject(s)

Antibodies, Anti-Idiotypic/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Asthma/therapy; Desensitization, Immunologic/methods; Rhinitis, Allergic/therapy; Adolescent; Adult; Asthma/immunology; Child; Disease Progression; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Omalizumab; Rhinitis, Allergic/immunology; Treatment Outcome; Young Adult

Key words

asthma; omalizumab; subcutaneous allergen-specific immunotherapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Antibodies, Anti-Idiotypic / Desensitization, Immunologic / Antibodies, Monoclonal, Humanized / Rhinitis, Allergic Type of study: Observational_studies / Prognostic_studies Limits: Adolescent / Adult / Child / Female / Humans / Male Language: En Journal: Pediatr Allergy Immunol Journal subject: ALERGIA E IMUNOLOGIA / PEDIATRIA Year: 2014 Document type: Article Affiliation country: France Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google